Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × SCLC,Extensive Stage × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 32 Breast Neoplasms 23 Triple Negative Breast Neoplasms 16 Prostatic Neoplasms 15 Fallopian Tube Neoplasms 11 Neoplasms 8 Pancreatic Neoplasms 6 Glioma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Fanconi Anemia, Complementation Group D1 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Neoplasm Metastasis 3 Medulloblastoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Wilms Tumor 2 Uveal Melanoma 2

Interventions

pembrolizumab 1 olaparib 1 niraparib 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡